/

BRTX

BioRestorative Therapies, Inc.Pre-market

1.59−0.16 −9.14%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.70

Prev close

1.75

Day range

1.441.71

52-week range

1.4434.40

Volume

32.38K1.23×

Mkt cap

2.20M

P/E ttm

—

Fwd P/E

-0.15

EPS ttm

-21.40

Div yield

0.00%

Earnings

—

From 52w high

−95.38%

Price Chart

Yahoo Finance · delayed

BRTXOct 13, 2026O 1.70H 1.71L 1.44C 1.59−0.16 (−9.14%)Vol 32.40K

SMA 501.53
SMA 2000.76

1Y change −0.62% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BRTX BioRestorative Therapies, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −29.96%
1 month: −40.45%
3 months: +381.82%
6 months: +546.34%
Year to date: +35.32%
1 year: −0.62%

Valuation & ownership

Market cap: 2.20M
Enterprise value: −1.54M
P/E (ttm): —
Forward P/E: -0.15
PEG ratio: —
Price / book: 0.67
Price / sales (ttm): 6.14
EV / EBITDA: 0.11
EPS (ttm): -21.40
EPS (forward): -10.40
Beta (5y monthly): 0.85
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 1.38M
Float: 1.21M
Short % of float: 0.97%
Short ratio (days): 0.37
Held by insiders: 6.22%
Held by institutions: 13.78%
Avg volume (3m): 26.35K
50-day average: 3.27
200-day average: 7.83
52-week change: −0.62%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 42.9
vs 50-day SMA: +3.81%
vs 200-day SMA: +110.08%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 19.21%
Realised vol (20d, ann.): 87.7%
From 52-week high: −71.95%
From 52-week low: +1,015.79%

ANR

Analyst Consensus

1 analysts

Consensus

Buy

2.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

300.00

+18,767.92% implied

Low 300.00Median 300.00High 300.00

Recommendation trend

Now1 / 1 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

Oct 6Maxim Group · Hold

DES

About BioRestorative Therapies, Inc.

Yahoo Finance profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 13
Headquarters: Melville, NY, United States
Website: biorestorative.com
Officers: Mr. Mika Grasso Interim CEO & Director
Ms. Anna Skowron CFO & Treasurer

SEAS

Seasonality · BRTX

2012–2026 · monthly returns

Strongest month Aug +1305.96%Weakest month Nov −17.49%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.0	-80.0	19.1	-17.3	112.4	-21.3	-45.6	-1.1	-42.4	-31.8			−93.2%
2025	66.4	-36.1	17.1	-1.1	-0.3	-5.1	-11.7	25.2	-21.2	6.2	-30.0	8.9	−17.8%
2024	-6.3	-14.1	-1.4	2.9	-12.0	62.4	-24.6	7.2	6.1	-10.3	-1.9	-6.5	−17.8%
2023	6.9	-5.8	22.7	16.5	31.3	-15.2	-34.5	-23.9	-18.6	10.6	-3.0	-9.4	−36.7%
2022	-21.9	64.0	-5.9	-19.3	-4.5	-26.8	4.4	6.3	-1.4	0.6	-5.5	-10.4	−36.6%
2021	52.2	39.0	-17.8	-16.7	-10.0	-33.3	-21.7	-27.7	5.9	-2.6	-57.2	-27.7	−84.3%
2020	-80.0	-80.0	-50.0	0.0	0.0	0.0	100.0	17050.0	-55.4	119.0	-57.9	-51.1	+38.0%
2019	-24.2	0.4	15.3	-27.7	-38.7	3.7	-17.4	-3.3	-24.1	-31.8	-72.1	-88.1	−99.4%
2018	-13.5	-2.5	1.9	-5.7	-32.0	-8.3	19.3	-11.7	-11.2	-34.3	-30.8	13.1	−75.7%
2017	28.8	-1.2	1.2	5.9	-20.0	-16.7	8.3	4.3	-4.1	7.7	-10.0	17.5	+12.1%
2016	-24.7	28.1	8.5	-9.0	-1.5	-7.3	-13.5	-1.6	4.8	3.0	-8.8	6.5	−22.4%
2015	2.2	0.0	-13.0	-7.5	18.9	-15.9	38.5	-19.5	-33.3	-44.5	44.3	-3.4	−52.8%
2014	28.5	0.2	-32.3	-29.6	59.8	-39.8	14.1	-2.9	6.0	0.0	14.0	12.8	−10.9%
2013	6.7	7.5	-21.5	-25.9	0.0	-27.0	9.6	-25.0	5.0	-4.8	-8.3	-8.2	−66.3%
2012													—

INSD

Insider Activity · BRTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.19B shares

Sells, 6 months

7.6K shares

Net shares

+1.19B

Net change in insider shares

−100.00%

Date	Insider	Transaction	Shares	Value
Oct 5, 2025	Silva FranciscoOfficer and Director	Stock Award(Grant) at price 1.60 per share.	11.7K	$18.75K
Oct 5, 2025	Alstodt LanceChief Executive Officer	Stock Award(Grant) at price 1.60 per share.	15.6K	$25.00K
Oct 27, 2024	Broadrick DaleBeneficial Owner of more than 10% of a Class of Security	Sale at price 1.58 per share.	1.1K	$1.76K

BRTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BRTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About BioRestorative Therapies, Inc.

Seasonality · BRTX

Insider Activity · BRTX

Congress Trades · BRTX

Investors Holding BRTX

Investors Holding BRTX

Congress Trades · BRTX

Insider Activity · BRTX

Seasonality · BRTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About BioRestorative Therapies, Inc.

Financial Snapshot

Earnings & Dividends

News